Neurogene Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Neurogene Inc. stock issued during period, value, new issues for the quarter ending 2026-06-30 was $5.90M.
- Neurogene Inc. stock issued during period, value, new issues for the quarter ending 2020-09-30 was $71.32M.
- Neurogene Inc. stock issued during period, value, new issues for fiscal 2024 was $189.50M, a 115.20% increase from fiscal 2023.
- Neurogene Inc. stock issued during period, value, new issues for fiscal 2023 was $88.06M.
- Neurogene Inc. stock issued during period, value, new issues for fiscal 2020 was $71.32M, a 11.61% decline from fiscal 2019.
- Neurogene Inc. stock issued during period, value, new issues for fiscal 2019 was $80.69M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2026-06-30 | $5.90M 10-Q · filed 2026-08-11 | |
| 2024-12-31 | $189.50M 10-K · filed 2026-03-24 | |
| 2023-12-31 | $88.06M 10-K · filed 2025-03-24 | |
| 2020-12-31 | $71.32M 10-K · filed 2022-03-01 | |
| 2020-09-30 | $71.32M 10-Q · filed 2021-11-04 | |
| 2019-12-31 | $80.69M 10-K · filed 2021-03-25 | |
| 2016-12-31 | $70.68M 10-K · filed 2019-03-07 | |
| 2015-12-31 | $91.79M 10-K · filed 2018-03-12 | |
| 2014-12-31 | $47.29M 10-K · filed 2017-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |